The Claim

In adults with type 2 diabetes and established cardiovascular disease, weekly subcutaneous tirzepatide (up to 15 mg) reduces the risk of a composite endpoint of major cardiorenal events—including all-cause mortality, myocardial infarction, stroke, coronary revascularization, heart failure hospitalization, and kidney disease progression—by 16% compared to weekly subcutaneous dulaglutide (1.5 mg) over a median follow-up of 47 months, with a hazard ratio of 0.84 (95% CI, 0.79–0.90).

Source: Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
74score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

In adults with type 2 diabetes and heart disease, a weekly injection of tirzepatide lowers the risk of serious heart and kidney events—such as heart attack, stroke, hospitalization for heart failure, or worsening kidney disease—by 16% compared to another drug called dulaglutide, when used for about 4 years.

See the scientific wording

In adults with type 2 diabetes and established cardiovascular disease, weekly subcutaneous tirzepatide (up to 15 mg) reduces the risk of a composite of major cardiorenal events—including all-cause mortality, myocardial infarction, stroke, coronary revascularization, heart failure hospitalization, and kidney disease progression—by 16% compared to dulaglutide (1.5 mg weekly) over a median follow-up of 47 months, with a hazard ratio of 0.84 (95% CI, 0.79–0.90).

Why this might work

Tirzepatide helps the body use insulin better and lose weight, which lowers blood sugar and fat levels. This reduces strain on the heart and kidneys, making it less likely for them to get damaged over time.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease

    In people with type 2 diabetes and heart disease, a new weekly shot called tirzepatide helped reduce serious heart and kidney problems by about 16% compared to another similar shot, dulaglutide, over nearly four years.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.